Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 1-Year Low – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) reached a new 52-week low on Thursday . The stock traded as low as $20.08 and last traded at $21.37, with a volume of 1439 shares changing hands. The stock had previously closed at $21.05.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CHGCY shares. UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Nomura raised shares of Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Down 1.2%

The company has a market capitalization of $68.00 billion, a PE ratio of 22.46 and a beta of 0.59. The company’s 50 day moving average is $21.99 and its two-hundred day moving average is $24.92.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The business had revenue of $2.14 billion for the quarter, compared to analysts’ expectations of $2.38 billion. Analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.